The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a safety warning for women using GLP-1 receptor agonist drugs, commonly known as weight loss injections like Ozempic and Mounjaro.
These medicines should not be used during pregnancy, while trying to conceive, or when breastfeeding. Women planning to get pregnant are advised to stop these drugs at least two months before attempting conception due to insufficient safety data on their effects on unborn babies.
The MHRA has received reports of pregnancies occurring in women taking these injections, sometimes unexpectedly despite contraception use.
Notably, Mounjaro may reduce the effectiveness of oral contraceptives in overweight users, so additional contraception such as condoms is recommended, especially during the first month and after any dose increase.
Dr. Alison Cave, MHRA Chief Safety Officer, emphasized that these drugs are medical treatments, not cosmetic quick fixes. She urged patients to carefully read information leaflets and consult healthcare professionals before use.
The warning highlights concerns over the rising off-label use of GLP-1 drugs for weight loss, which were originally approved to treat type 2 diabetes but have gained popularity for their appetite-suppressing effects and weight reduction benefits.
Despite their effectiveness, experts caution about potential risks and the need for careful medical supervision.
Related topics:
- Weighted Plush Toys Offer Portable Relief for Anxiety and Stress
- High Costs of Weight-Loss Drugs: What You Need to Know
- Why Women Over 35 Need to Lift Weights, Says Expert
